Clinical trials: Colitis, Ulcerative
Ulcerative Colitis, IBD
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by…
- Trial name
- Expedition (NCT03616821)
- Testing
- Brazikumab
- Where
- 125 sites in United States, Canada and 17 more
- Volunteers
- 242 people
- Sponsor
- AstraZeneca
Acute Ulcerative Colitis
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05.
- Trial name
- Precision-UC (NCT01903252)
- Testing
- TP05, Asacol 400 mg
- Where
- Switzerland
- Volunteers
- 817 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX) in treating ulcerative colitis and examine the drug's effect on the immune system.
- Trial name
- NCT00048347
- Testing
- AVONEX
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ulcerative Colitis
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity…
- Trial name
- NCT00801723
- Testing
- Budesonide MMX 6 mg Tablet
- Where
- 58 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome, Ulcerative Colitis
Efficacy of Gralise® for Chronic Pelvic Pain
This study is done to investigate the pain relieving effects of the study drug Gralise (a novel long acting gabapentinoid) for people who experience chronic pelvic pain.
- Conditions
- Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis
- Trial name
- NCT01678911
- Testing
- Gralise
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shirley Ryan AbilityLab
Ulcerative Colitis
Xeljanz Special Investigation for Long-term Use in UC Patients
Secondary data collection study: safety and effectiveness of Xeljanz in UC patients under Japanese medical practice
- Trial name
- NCT03643211
- Where
- Japan
- Volunteers
- 2,016 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis…
- Trial name
- OCTAVE (NCT01465763)
- Testing
- tofacitinib
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 614 people
- Sponsor
- Pfizer
Ulcerative Colitis
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
The purpose of this study was to evaluate efficacy of cobitolimod treatment at different dose levels and frequencies compared to placebo in patients with moderate to severe left-sided ulcerative colitis.
- Trial name
- CONDUCT (NCT03178669)
- Testing
- cobitolimod
- Where
- 64 sites in Czechia, France and 8 more
- Volunteers
- 213 people
- Sponsor
- InDex Pharmaceuticals
Ulcerative Colitis
Efficacy and Safety of BBT-401-1S in Ulcerative Colitis
This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis.
- Trial name
- NCT03800420
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- Bridge Biotherapeutics, Inc.
Colitis, Ulcerative
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- VEGA (NCT03662542)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1
- Where
- 82 sites in United States, Argentina and 7 more
- Volunteers
- 214 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Dose Escalation and Remission (DEAR)
The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative…
- Trial name
- DEAR (NCT00652145)
- Testing
- mesalamine
- Where
- 8 sites in United States
- Volunteers
- 119 people
- Sponsor
- James Lewis
Inflammatory Bowel Disease, Crohn's Disease
Bacteriotherapy in Pediatric Inflammatory Bowel Disease
In this study, the investigators want to see if Bacteriotherapy (also referred to as stool transplantation) improves the symptoms and decreases inflammation in children with Inflammatory Bowel Disease (IBD).
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, CD
- Trial name
- NCT01757964
- Testing
- Bacteriotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- David Suskind
Ulcerative Colitis
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
- Trial name
- GLADIATOR UC (NCT04607837)
- Testing
- Etrasimod
- Where
- 288 sites in United States, Australia and 16 more
- Volunteers
- 234 people
- Sponsor
- Pfizer
Colitis, Ulcerative, Crohn Disease
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
The purpose of this study is to monitor ongoing safety in participants with ulcerative colitis (UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying participants who, in the opinion of the…
- Trial name
- NCT02743806
- Testing
- Vedolizumab
- Where
- 78 sites in Australia, Bulgaria and 16 more
- Volunteers
- 331 people
- Sponsor
- Takeda
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Colitis, Ulcerative, Inflammatory Bowel Disease
Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
To assess if infliximab drug levels in subjects with Ulcerative Colitis predict risk of colectomy rate. Additionally, the investigators will estimate an optimal day 4 infliximab level based on the study results.
- Conditions
- Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
- Trial name
- NCT02438410
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Ulcerative Colitis
Melatonin and Ulcerative Colitis: A Pilot Clinical Trial
Ulcerative colitis is an inflammatory bowel disease that afflicts up to one million people in the U.S. Symptoms include rectal urgency, bloody diarrhea, moderate to severe abdominal pain, fever, and fatigue.
- Trial name
- NCT00790478
- Testing
- Melatonin
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Colitis, Ulcerative
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- ASTRO (NCT05528510)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 236 sites in United States, Argentina and 23 more
- Volunteers
- 418 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases, Ulcerative Colitis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- Trial name
- CONNECT-IBD (NCT02539368)
- Testing
- CT-P13, Remicade
- Where
- 140 sites in Belgium, Czechia and 11 more
- Volunteers
- 2,565 people
- Sponsor
- Pfizer
Ulcerative Colitis
MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with moderate to severe UC
- Trial name
- NCT01959165
- Testing
- MEDI7183 low dose, MEDI7183 medium dose, MEDI7183 high dose
- Where
- 23 sites in Japan
- Volunteers
- 44 people
- Sponsor
- AstraZeneca